United States: FTC/DOJ Remove Mandatory Antitrust Review For MSSP-Participating ACOs In Final Policy Statement

On October 20, 2011, the Federal Trade Commission and Department of Justice issued a final policy statement on accountable care organizations (ACOs) participating in the Medicare Shared Savings Program (MSSP). Significantly, the Agencies eliminated mandatory antitrust review of certain ACOs seeking to participate in the MSSP, but declined to adopt other stakeholder recommendations.

Introduction

On October 20, 2011, the Federal Trade Commission (FTC) and Department of Justice (DOJ and, with the FTC, an Agency, and, collectively, the Agencies) issued a final "Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program" (Policy Statement). The final Policy Statement differs from the Policy Statement the Agencies proposed in March 2011 in a couple of key respects, but does not incorporate many other comments that stakeholders submitted in response to the proposed Policy Statement. Most significantly, the Agencies eliminated mandatory antitrust review prior to participation in the Medicare Shared Savings Program (MSSP) for accountable care organizations (ACOs) with a combined primary service area (PSA) share in excess of 50 percent in any common service. In its place, the Agencies implemented a process for "newly formed" ACOs to seek expedited voluntary antitrust review.

Background

The Policy Statement provides that the Agencies will apply rule of reason—and not per se—analysis to an ACO's joint contracting activities with commercial payors, so long as the ACO meets the U.S. Centers for Medicare & Medicaid Services' (CMS') requirements for participation—and participates—in the MSSP, and uses the same governance structures and clinical processes to serve patients in Medicare and commercial markets. The Policy Statement also creates a safety zone providing that the Agencies will not challenge, absent extraordinary circumstances, an ACO comprising independent ACO participants providing a common service that possess a combined share of 30 percent or less of each common service in each participant's PSA. View FTC/DOJ Issue Joint Proposed Statement of Antitrust Enforcement Policy Relating to ACOs for an in-depth summary of the key provisions of the proposed Policy Statement, most of which were retained in the final Policy Statement.

Changes: The Good and the Bad

Elimination of Mandatory Review Lowers Burden on ACOs

The most significant difference between the proposed and final Policy Statement is the elimination of mandatory Agency antitrust review as a prerequisite for participation in the MSSP, which, under the proposed Policy Statement, was required for ACOs with a PSA share in excess of 50 percent in any service common to independent ACO participants. This revision removes a burdensome and broad production of information to the Agencies.

Availability of Voluntary Expedited Review Is Useful, but Agency Selection Could Be Outcome Determinative

Having eliminated mandatory antitrust review, the final Policy Statement provides that "newly formed" ACOs seeking further antitrust guidance may voluntarily request from the Agencies an expedited 90-day antitrust review prior to participation in the MSSP. Newly formed ACOs are ACOs that, as of March 23, 2010, "had not yet signed or jointly negotiated any contracts with private payors" and have not yet participated in the MSSP. Both an ACO's request letter and the Agency's response will be made public consistent with confidentiality provisions pertaining to competitively-sensitive information. An ACO must submit its request to both the FTC and DOJ, who will determine which Agency will review the request (although they have not disclosed how they will allocate requests between them). Although the Policy Statement notes that it has been the Agencies' practice to share with each other their proposed business review and staff advisory opinion letters before issuing them in final form to ensure application of consistent standards of antitrust review, this dual-Agency review system would seem to increase the likelihood of inconsistencies in antitrust analyses and, with differences between the Agencies in their approach to antitrust enforcement, the decision as to which Agency will review a particular ACO could play a significant role in the outcome of the review.

Expansion of Applicability of Policy Statement Provides Certainty of Rule of Reason Treatment to More ACO Collaborations but Leaves Purely Commercial ACOs Without Safe Harbors

The applicability of the final Policy Statement is no longer limited to collaborations formed after March 23, 2010 (the date on which the Patient Protection and Affordable Care Act was enacted), but rather applies to all collaborations of otherwise independent providers and provider groups that are eligible and intend, or have been approved, to participate in the MSSP. This revision will provide the certainty of rule of reason treatment to a greater number of ACOs. Yet, the Policy Statement still does not apply to ACOs whose programs are substantially similar to ACOs participating in the MSSP, but provide services to commercially insured patients only. Those organizations will not have the benefit of the safe harbor, which could discourage or deter the formation of potentially efficiency-enhancing collaborations. One could expect, though, that the analytical framework of the Policy Statement will nevertheless be instructive for ACOs participating only in the commercial marketplace. Similarly, a footnote to the Policy Statement indicates that "the analytical principles underlying the Policy Statement also would apply to various ACO initiatives undertaken by the Innovation Center within CMS as long as those ACOs are substantially clinically or financially integrated," but comes short of expressly applying the Policy Statement to ACOs participating in programs through the Center for Medicare & Medicaid Innovation, such as the Pioneer ACO program.

Two other clarifications about the Policy Statement's applicability are noteworthy. Large, vertically integrated health systems can take comfort in the guidance that the Policy Statement does not apply to single, fully integrated entities. Moreover, the final Policy Statement addresses confusion as to what entities constitute ACO participants by defining an ACO participant as an independent physician solo practice, a fully integrated physician group practice, an inpatient facility or an outpatient facility. Stakeholders should be aware that the Policy Statement's definition of ACO participant may differ from CMS's.

PSA Shares May Not Accurately Predict Market Share or Market Power

The final Policy Statement retained the proposed method of calculating physician PSA shares based on Medicare fee-for-service allowed charges. While the selection of this measure of shares reflects the limitation of available data, shares based on Medicare revenues may not accurately predict the market share of collaborating physicians who provide a common service, as not all participating physicians may participate in Medicare and, even if they do, they may not share the same payor mix.

Medical providers interested in establishing an ACO should work diligently to assess antitrust risk, especially when PSA shares exceed 30 percent. A relatively low 30 percent safety zone means that many ACOs will not be insulated from Agency review. And even if they do fall within the safety zone, ACOs must remember that the Policy Statement does not shield them from a state challenge or private challenge.

Rural Exception

The Agencies also expanded the rural exception from one physician per specialty from each rural county to one physician or integrated physician group practice per specialty from each rural area. This change eliminates the impracticality the proposed Policy Statement created of having to choose only one physician—and not all physician members—of an integrated group practice. Under the rural exception as revised, an ACO may include on a non-exclusive basis one physician or one physician practice per specialty from each rural area and still otherwise qualify for the safety zone, so long as the physician or group practice's primary office is in a ZIP code that the WWAMI Rural Health Research Center of the University of Washington has classified as "isolated rural" or "other small rural."

For physician groups to qualify for the rural exception, the group practice must have been an integrated group practice as of the date of the final Policy Statement. The Agencies also changed the geographic definition from a rural county (as defined by the U.S. Census Bureau) to a rural area, which is any county containing at least one zip code that the WWAMI Rural Health Research Center of the University of Washington has classified as "isolated rural" or "other small rural."

The Agencies also added a third category of rural hospitals that are eligible for the rural exception. In addition to a sole community hospital and a critical access hospital, any other acute care hospital located in a rural area that has no more than 50 acute care inpatient beds and is located at least 35 miles from any other inpatient acute care hospital may also be eligible for the exception. The rural exception provides that an ACO may include rural hospitals on a non-exclusive basis and still qualify for the safety zone, even if the inclusion of a rural hospital causes the ACO's share of any common service to exceed 30 percent in any ACO participant's PSA.

Conclusion

Although the Agencies eliminated mandatory antitrust review for certain ACOs prior to participation in the MSSP, the Agencies state they will "vigilantly" monitor complaints about an ACO's formation or conduct and take appropriate enforcement action.

The Policy Statement identifies five categories of conduct that, under certain circumstances, may raise competitive concerns and, therefore, are likely to draw Agency scrutiny. Irrespective of PSA shares, the Agencies caution against the exchange of competitively sensitive information among ACO participants that could facilitate collusion among ACO participants in the sale of competing services outside of the ACO. The Agencies further recommend that ACOs with high PSA shares or other indicia of market power avoid:

  • Preventing or discouraging commercial payors from steering patients to other providers
  • Tying sales of the ACO's services to the payor's purchase of other services from providers outside the ACO
  • Contracting with ACO participants on an exclusive basis
  • Restricting a payor's ability to disclose to its beneficiaries cost and quality data.

ACOs should, therefore, be mindful of the competitive implications of their contracting activities in the marketplace.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions